sb 203580 has been researched along with trientine in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (trientine) | Trials (trientine) | Recent Studies (post-2010) (trientine) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 450 | 12 | 158 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| ENDOH, D; HAYASHI, M; KADOWAKI, S; OKUI, T | 1 |
1 other study(ies) available for sb 203580 and trientine
| Article | Year |
|---|---|
Trientine, a copper-chelating agent, induced apoptosis in murine fibrosarcoma cells by activation of the p38 MAPK pathway.
Topics: Animals; Apoptosis; Cell Line, Tumor; Chelating Agents; Copper; Enzyme Activation; Fibrosarcoma; Imidazoles; Mice; p38 Mitogen-Activated Protein Kinases; Pyridines; Signal Transduction; Trientine | 2009 |